Repurposing of sericin combined with dactolisib or vitamin D to combat non-small lung cancer cells through computational and biological investigations

• Published in: Scientific reports Vol. 14; no. 1; pp. 27034 - 24
• Main Authors: Helmy, Maged W., Youssef, Mariam H., Yamari, Imane, Amr, Alaa, Moussa, Farouzia I., El Wakil, Abeer, Chtita, Samir, El-Samad, Lamia M., Hassan, Mohamed A.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 07.11.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/114; 631/154; 631/45; 631/67; AKT protein; Apoptosis; Caspase-3; Cell proliferation; Cyclin D1; Dactolisib; Drug delivery; Drug dosages; Drug interaction; Humanities and Social Sciences; Lung cancer; multidisciplinary; NF-κB protein; Non-small lung cancer cells; Nuclear factor Kappa B (NF-κB); Protein interaction; Science; Science (multidisciplinary); Sericin; Vitamin D; In silico studies; Vitamin D; Nuclear factor Kappa B (NF-κB); Vascular endothelial growth factor 1 (VEGF1); Protein-protein interaction; Lung cancer; Sericin; Phospho-akt (p-AKT); Dactolisib; Non-small lung cancer cells; Cyclin D1
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-76947-0

This study aims to repurpose sericin in combating non-small lung cancer cells (A549 and H460) by combining it with dactolisib or vitamin D to reduce the dose of dactolisib and boost the anticancer effectiveness of dactolisib and vitamin D. Therefore, the binding affinities of individual and combined drugs were examined using in silico and protein-protein interaction studies, targeting NF-κB, Cyclin D1, p-AKT, and VEGF1 proteins. The findings manifested remarkable affinities for combinatorial drugs compared to individual compounds. To substantiate these findings, the combined IC 50 for each combination (sericin + dactolisib and sericin + vitamin D) were determined, reporting 31.9 and 41.8 µg/ml, respectively, against A549 cells and 47.9 and 55.3 µg/ml, respectively, against H460 cells. Furthermore, combination indices were assessed to lower the doses of each drug. Interestingly, in vitro results exhibited marked diminutions in NF-κB, Cyclin D1, p-AKT, and VEGF1 after treatment with sericin + dactolisib and sericin + vitamin D compared to control lung cancer cells and those treated with a single drug. Moreover, A549 and H460 cells treated with both combinations demonstrated augmented caspase-3 levels, implying substantial apoptotic activity. Altogether, these results accentuated the prospective implementation of sericin in combination with dactolisib and vitamin D at low doses to preclude lung cancer cell proliferation.